MoonLake Immunotherapeutics (MLTX)
- Previous Close
42.63 - Open
42.59 - Bid 42.13 x 100
- Ask 42.74 x 100
- Day's Range
42.05 - 42.84 - 52 Week Range
24.31 - 64.98 - Volume
55,163 - Avg. Volume
466,857 - Market Cap (intraday)
2.67B - Beta (5Y Monthly) 1.19
- PE Ratio (TTM)
-- - EPS (TTM)
-0.73 - Earnings Date May 12, 2024 - May 16, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
70.93
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.
www.moonlaketx.comRecent News: MLTX
Performance Overview: MLTX
Trailing total returns as of 5/9/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MLTX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MLTX
Valuation Measures
Market Cap
2.68B
Enterprise Value
2.17B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
5.41
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-40.16
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-11.21%
Return on Equity (ttm)
-15.14%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-36.01M
Diluted EPS (ttm)
-0.73
Balance Sheet and Cash Flow
Total Cash (mrq)
511.01M
Total Debt/Equity (mrq)
0.72%
Levered Free Cash Flow (ttm)
-24.5M
Research Analysis: MLTX
Company Insights: MLTX
MLTX does not have Company Insights